Objectives To explore the relationships among dose, time and effect of cytarabine (Ara-C) treatment in acute leukemia. Methods In the presence of designated Ara-C dosage gradient (0.1 - 200 |xmol/L) and times (4 - 48 h), CCK-8 assay were used to analyze the differences and regularity of inhibition of human leukemia cloned strains Jurkat (ALL) and NB4 (AML). Results In the designated Ara-C concentrations, the inhibition rates of proliferation of Jurkat and NB4 were gradually increased with increasing time exposed to Ara-C. In the designated groups with presence of Ara-C effecting for 4 h and 8 h, the inhibition rates of Jurkat were obviously increased by presence of increasing doses exposed, however, this kind of correlation of dose exposure and inhibition rates showed only in doses of 0.5 - 50 μmol/L for NB4. Conclusions As a cell cycle specific agent, the correlation between its effecting dose and time of proliferation inhibition of Ara-C was significant, and Jurkat cell lines were more sensitive to Ara-C than were NB4 cell lines.%目的 探索阿糖胞苷(Ara-C)治疗急性白血病的剂量、时间与效应的相关性.方法 采用CCK-8法.检测不同剂量梯度范围内(0.1～200 μmol/L)、Ara-C作用不同时间(4～48h),对白血病细胞株Jurkat (ALL)和NB4(AML)增殖抑制作用的差异与特征规律.结果 Jurkat细胞和NB4细胞在一定的Ara-C作用浓度范围内,均存在着随作用时间延长,增殖抑制逐渐提升的效应.在4h和8h2个作用时间组中,随着Ara-C剂量递增,Jurkat细胞的增殖抑制率明显增加;而NB4细胞仅在0.5～50μmol/L浓度梯度范围内呈现剂量与效应的相关性.结论 Ara-C作为细胞周期特异性药物(CCSA),对肿瘤细胞的增殖抑制效应存在明显的时间-剂量相关性,Jurkat对Ara-C的敏感性高于NB4.
展开▼
